Reza Halse will be a partner at RA Capital, which held a first and final closing of its second venture fund in October. 

China Merchants Group led a series C round for the antibody drug developer that was also backed by fellow corporates Tigermed and Dawn.

Boehringer Ingelheim Venture Fund returned to reinvest in the regenerative therapy developer after backing its series A round two years ago.

The Future Value Fund I will invest in pre-seed companies, including spinouts from Rev1's long-time partner Ohio State University.

The regenerative therapy developer is based on research at University of Torino and has raised capital from returning backer V-Bio Ventures.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Synthetic biology-based vaccin developer Delonix Bioworks has completed a round co-led by Boehringer Ingelheim Venture Fund.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The Transamerica and Scor-backed patient monitoring system developer has announced it has secured $25m in its seed round.

Technology-equipped healthcare membership service Forward Health has raised $225m from investors including SoftBank Vision Fund 2 at a valuation exceeding $1bn.